Roche Holdings AG (OTC:RHHBY) reported fiscal 2025 sales of 61.5 billion Swiss Francs (around $76.96 billion), up 7% (+2% in CHF) due to strong demand for pharmaceutical products and diagnostic solutions.
Core operating profit increased by 13% (5% in CHF) to CHF 21.8 billion, driven by higher sales and efficiency gains.
Core EPS increased 11% (+4% in CHF) to CHF 19.46 ($24.35).
Segment Performance
Sales in the Pharmaceuticals Division increased by 9% (3% in CHF) to CHF 47.7 billion, with medicines for severe diseases continuing their strong growth.
The top five growth drivers – Phesgo, Xolair, Ocrevus, Hemlibra, and Vabysmo – achieved total sales of CHF 21.4 billion, an increase of CHF 3.2 billion (CER) compared to 2024.
Ocrevus sales were up 9% to CHF 7.01 billion, Hemlibra sales jumped 11% to CHF …